

THE HEP573 STUDY: A randomised, double-blind, placebo-controlled clinical trial of silymarin alone, and silymarin combined with antioxidants in chronic hepatitis C

ACTRN12614000966695

Status	COMPLETED
Phase	Phase 2
Sponsor	John Hunter Hospital
Enrollment	216 participants

Key Eligibility Criteria

Inclusion (8)

- (1) able to give informed consent;
 - (2) aged between 18 and 75 years;
 - (3) hepatitis C antibody and HCV RNA positive;
 - (4) abnormal liver tests on at least three occasions in the past two years;
 - (5) prepared to stop Western and Chinese herbs, vitamins and nutritional supplements used in the Study for the study duration and for a wash out period of 12 weeks prior to trial entry;
- ... and 3 more (see full listing online)

Exclusion (17)

- (1) Alcohol-related liver disease;
 - (2) alpha 1-antitrypsin deficiency;
 - (3) autoimmune hepatitis;
 - (4) drug-induced liver disease;
 - (5) haemochromatosis;
- ... and 12 more (see full listing online)

Locations (3 total)

John Hunter Hospital Royal Newcastle Centre - New Lambton, NSW, Australia
Royal Prince Alfred Hospital - Camperdown, NSW, Australia
Westmead Hospital - Westmead, NSW, Australia